Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could everyday chemicals raise risk of birth defect? new study investigates

NCT ID NCT06628375

Recruiting now Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether exposure to certain chemicals (endocrine disruptors) during pregnancy increases the chance of a baby boy being born with hypospadias, a condition where the opening of the urethra is not at the tip of the penis. Researchers will compare 100 mothers of boys with hypospadias to 100 mothers of boys without it. They will test hair samples for 150 chemicals and use questionnaires to measure overall exposure. The goal is to better understand and potentially prevent this birth defect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help identify specific pollutants that raise the risk of hypospadias, leading to better prevention advice for pregnant women.
What could go wrong
This is an observational study, not a treatment trial. It can show links but not prove cause and effect. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOSPADIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Congenital Abnormalities hypospadias

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOSPADIAS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CRMR DEVGEN CHU Lapeyronnie

    RECRUITING

    Montpellier, Hérault, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.